New Market - November 5, 2025
Moberg Pharma and Karo Healthcare in license agreement
Moberg Pharma has entered into an exclusive licensing agreement with Karo Healthcare regarding the commercialization of MOB-015 (Terclara) in Europe.
Collaboration - October 27, 2025
Lundbeck in strategic collaboration with OpenAI
Through the deployment of ChatGPT Enterprise to its global workforce, Lundbeck will empower employees with AI capabilities designed to accelerate discovery, enhance decision-making, and drive unprecedented efficiency, it states.
Agreement - October 23, 2025
Medivir enters licensing agreement with Biossil
Medivir has entered into an exclusive licensing agreement, through which Biossil, Inc. will receive global, exclusive development rights for remetinostat, a clinical-stage topical HDAC inhibitor.
Collaboration - October 20, 2025
Lundbeck and Contera Pharma enter research collaboration
The two companies have announced a strategic research collaboration aiming to accelerate the discovery and development of innovative oligonucleotide-based medicines for patients living with serious neurological conditions.
Pharma Business - October 16, 2025
Novo Nordisk and Omeros enter purchase and license agreement
The companies have entered into a definitive asset purchase and license agreement for the candidate drug zaltenibart (formerly OMS906) in clinical development for rare blood and kidney disorders.
Pharma Business - October 15, 2025
Lundbeck receives Breakthrough Therapy Designation in China
The company's investigational drug bexicaserin, for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs), has been granted Breakthrough Therapy Designation (BTD) by China's Center for Drug Evaluation (CDE).
